94 related articles for article (PubMed ID: 22118544)
21. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
22. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
23. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
24. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
[TBL] [Abstract][Full Text] [Related]
25. Production of Epitope-Specific Antibodies by Immunization with Synthetic Epitope Peptide Formulated with CpG-DNA-Liposome Complex Without Carriers.
Kim D; Lee Y; Kwon HJ
Methods Mol Biol; 2015; 1348():127-35. PubMed ID: 26424269
[TBL] [Abstract][Full Text] [Related]
26. Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers.
Lee Y; Lee YS; Cho SY; Kwon HJ
Adv Protein Chem Struct Biol; 2015; 99():75-97. PubMed ID: 26067817
[TBL] [Abstract][Full Text] [Related]
27. Immunostimulatory sequence oligdeoxynucleotide/cholera toxin B conjugate: a novel allergen-independent intranasal vaccine for allergic rhinitis.
Won TB; Quan SH; Kim DY; Rhee CS; Lee CH
Ann Allergy Asthma Immunol; 2009 Apr; 102(4):314-22. PubMed ID: 19441603
[TBL] [Abstract][Full Text] [Related]
28. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
Liu Y; Luo X; Yang C; Yu S; Xu H
Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
[TBL] [Abstract][Full Text] [Related]
29. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway.
Xu W; Tamura T; Takatsu K
Int Immunopharmacol; 2008 Feb; 8(2):351-61. PubMed ID: 18182251
[TBL] [Abstract][Full Text] [Related]
30. Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.
Rhee JW; Kim D; Park BK; Kwon S; Cho S; Lee I; Park MS; Seo JN; Kim YS; Choi HS; Lee Y; Kwon HJ
PLoS One; 2012; 7(11):e48750. PubMed ID: 23144954
[TBL] [Abstract][Full Text] [Related]
31. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
33. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
34. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant.
Guo L; Chen J; Qiu Y; Zhang S; Xu B; Gao Y
Int J Pharm; 2013 Apr; 447(1-2):22-30. PubMed ID: 23410987
[TBL] [Abstract][Full Text] [Related]
35. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA.
Kim D; Rhee JW; Kwon S; Sohn WJ; Lee Y; Kim DW; Kim DS; Kwon HJ
Biochem Biophys Res Commun; 2009 Feb; 379(2):362-7. PubMed ID: 19103173
[TBL] [Abstract][Full Text] [Related]
36. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants.
Lipford GB; Bauer M; Blank C; Reiter R; Wagner H; Heeg K
Eur J Immunol; 1997 Sep; 27(9):2340-4. PubMed ID: 9341778
[TBL] [Abstract][Full Text] [Related]
37. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
38. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
Agallou M; Margaroni M; Karagouni E
Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
[TBL] [Abstract][Full Text] [Related]
39. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
Wattrang E; Berg M; Magnusson M
Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
[TBL] [Abstract][Full Text] [Related]
40. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
